MODAG GmbH news
TEL AVIV & WENDELSHEIM, Germany--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG`s lead compound anle138b and a related compound, sery433.
MODAG, a German biotechnology company focused on the development of disease-modifying small molecule therapeutics for neurodegenerative diseases, today announced the clinical trial initiation of a first-in-patient Phase 1b study for anle138b in patients with mild to moderate Parkinson´s Disease (PD). Anle138b is a disease-modifying treatment option for synucleinopathies, such as Multiple System Atrophy (MSA) and PD.
The short-term Phase 1b study with PD patients will be conducte
MODAG, a German biotechnology company focused on the development of disease-modifying small molecule therapeutics for neurodegenerative diseases, today announced the successful completion of its first clinical trial of anle138b (NCT04208152) in healthy volunteers. The Company’s lead candidate, which was administered in doses of up to 300 mg daily, demonstrated excellent safety and tolerability profiles at all dose levels and reached significantly higher plasma levels in humans than thos
MODAG, a German biotechnology company focused on the development of disease-modifying small molecule therapeutics for neurodegenerative diseases, today announced the clinical trial initiation of, and recruitment for, a first-in-human Phase 1 study of lead candidate, anle138b in healthy volunteers. The compound is initially being developed for the treatment of Multiple System Atrophy (MSA), with the potential to be applied to other synucleinopathies,such as Parkinson’s disease, in the fu
MODAG today announced the appointment of Johannes Levin, M.D., as Chief Medical Officer (CMO). Dr. Levin brings with him over ten years of experience in the field of movement disorders, particularly in atypical Parkinsonism such as Multiple System Atrophy (MSA), along with a strong scientific background in protein aggregation. He recently led a clinical MSA study with Prof. Dr. Armin Giese, CSO of MODAG; the findings were published in The Lancet Neurology. At MODAG, Dr. Levin will be responsi
MODAG announced today the completion of a EUR 12 million Series A financing round, launching out of stealth mode to advance lead candidate anle138b into clinical development in Multiple System Atrophy (MSA). The company was founded in 2013 based on research conducted by Prof. Dr. Giese (Ludwig Maximilian University of Munich) and Prof. Dr. Griesinger(Max-Planck-Institute for Biophysical Chemistry) examining protein aggregation and its toxic properties in neurodegenerative diseases to develop